FDA extends review of Alexza product, shares fall - Reuters
Proactive Investors USA & CanadaFDA extends review of Alexza product, shares fallReutersAdasuve combines Alexza's Staccato system -- a hand-held, single-dose inhaler that delivers a medication comparable to intravenous administration -- with loxapine, an anti-psychotic that is available as an oral drug for schizophrenia.
FDA Should Not Approve Drug That Is Likely to Cause Life-Threatening Lung Toxicity - NewDesignWorld (press release)
FDA Should Not Approve Drug That Is Likely to Cause Life-Threatening Lung ToxicityNewDesignWorld (press release)The drug, loxapine inhalation powder (also known as Adasuve), manufactured by Alexza Pharmaceuticals, is the first inhaled form of an antipsychotic for use in schizophrenic or bipolar patients.
FDA review of Alexza's Adasuve delayed - PMLiVE
FDA review of Alexza's Adasuve delayedPMLiVEAdasuve (loxapine) is Alexza's lead product and is intended as a more patient-friendly alternative to injectable antipsychotics used to treat agitation in patients with schizophrenia or bipolar mania.
Valeant Pharmaceuticals (VRX) Downgraded by Piper Jaffray (PJC) - LocalizedUSA
Valeant Pharmaceuticals (VRX) Downgraded by Piper Jaffray (PJC)LocalizedUSAAs of December 31, 2009, the Company's products within its development pipeline included Staccato loxapine, Pimavanserin, BVF-018, Fipamezole and GDNF.